Video

Dr. Parker on next steps with mpMRI in prostate cancer

Author(s):

Urology Times staff

William P. Parker, MD, shares his expectations for the future of multiparametric MRI (mpMRI) in prostate cancer and where micro-ultrasound may fit alongside mpMRI in the paradigm. Parker is a practicing urologist at The University of Kanas Health System and an assistant professor at the University of Kansas Medical Center.

Related Videos
Prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
Eric Li, MD, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Related Content
Man Receiving Medical Scan for Prostate Cancer Diagnosis | Image Credit: © Mark Kostich - stock.adobe.com
December 18th 2024

Top 10 urologic imaging stories in 2024

Benjamin P. Saylor
As the year comes to a close, we revisit some of this year’s top content on next-generation imaging agents in urology.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Head-to-head trial to compare 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 PET/CT
November 19th 2024

Head-to-head trial to compare 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 PET/CT

Hannah Clarke
The primary objective is to compare the detection rate of sites of prostate cancer recurrence between the 2 agents.
Dr. Bristol Whiles discusses her experience as a urology resident
July 25th 2022

Dr. Bristol Whiles discusses her experience as a urology resident

Kansas University Department of Urology
On this podcast, Bristol Whiles, MD, discusses her urology residency experience at the Kansas University School of Medicine Department of Urology.
Study to inform definitive trial of 99mTc-sestaMIBI SPECT/CT for T1 renal tumors
November 12th 2024

Study to inform definitive trial of 99mTc-sestaMIBI SPECT/CT for T1 renal tumors

Hannah Clarke
The sensitivity of 99mTc-sestaMIBI SPECT/CT was 97%, and the specificity was 53.8%.
CMS adjusts reimbursement for diagnostic radiopharmaceuticals
November 5th 2024

CMS adjusts reimbursement for diagnostic radiopharmaceuticals

Hannah Clarke
The revised policy will take effect on January 1, 2025.
© 2024 MJH Life Sciences

All rights reserved.